Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

physical activity and diet on obesity. Among the data Eckel discussed were findings from the SURMOUNT-OSA trial, which assessed the impact of tirzepatide (Zepbound, Eli Lilly) on apnea-hypopnea ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly, an American pharmaceutical ... CEO Ricks said, "Tirzepatide has confirmed efficacy for diabetes, obesity, sleep apnea, and now heart failure," adding that "we are gradually expanding ...